| Product | CAS NO. | Therapeutic Category | CHINA | US | EU | JAPAN | OTHERS |
|---|---|---|---|---|---|---|---|
| Apixaban | 503612-47-3 | Cardiovascular | TP | ||||
| Apalutamide | 956104-40-8 | Oncology | TP | ||||
| Brivaracetam | 357336-20-0 | Neurology & Psychiatry | TP | ||||
| Bosutinib | 380843-75-4 | Oncology | TP | ||||
| Dacomitinib | 1110813-31-4 | Oncology | TP | ||||
| Empagliflozin | 864070-44-0 | Anti-diabetes | ▲ | TP | |||
| Ibrutinib | 936563-96-1 | Oncology | ▲ | ▲ | ▲ | TP | |
| Lacosamide | 175481-36-4 | Neurology & Psychiatry | TP | ||||
| Nilotinib HCL | 641571-10-0 | Oncology | ▲ | ▲ | TP | ||
| Nintedanib | 656247-17-5 | Oncology | TP | ||||
| Relugolix | 737789-87-6 | Oncology | TP | ||||
| Ruxolitinib Phosphate | 1092939-17-7 | Oncology | TP |
▲ CTD dossier under filling/preparation
According to laws and regulations of People's Republic of China, relevant information of Schedule II Controlled Substance APIs is not released here.
Disclaimer: The product that is still under patent protection can only be used in research and development, not for commercial purpose.
<i id='e103b'><strike id='58614'><tt id='daae8'><pre id='7afc5'></pre></tt></strike></i>